The purpose of the trial is to evaluate the safety and pharmacokinetics of GEN1046 in Japanese subjects with malignant solid tumors.
This is an open-label, single-country, multicenter, phase 1 dose escalation trial to assess the safety and pharmacokinetics (PK) of GEN1046.